Starting a Revolution Isn’t Enough
In an op-ed for The Atlantic, CRISPR pioneer Jennifer Doudna reflects on the state of biotechnology and poses the question, “Are we dreaming big enough? Moving quickly enough?”
Ensuring that CRISPR reaches its full potential for clinical applications and beyond will require a high level of intentional building with diverse and dedicated collaborators. Governments, universities, and investors will need to make significant and sustained investment in cutting-edge science at labs and at biotechnology companies, as well as investments in infrastructure and manufacturing to ensure that this work is scalable.
Powerful technology, of course, comes with the potential for misuse, and CRISPR’s powers raise important questions.
Read the full op-ed in The Atlantic.